[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@ThePharmaLetter Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::71542880.png) @ThePharmaLetter The Pharma Letter

The Pharma Letter posts on X about superior, acquisition, surge, $226m the most. They currently have XXXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::71542880/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::71542880/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXX +125%
- X Months XXXXXX +77%
- X Year XXXXXX +32%

### Mentions: XX [#](/creator/twitter::71542880/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::71542880/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XX +119%
- X Months XXX +39%
- X Year XXX +95%

### Followers: XXXXXX [#](/creator/twitter::71542880/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::71542880/c:line/m:followers.svg)

- X Week XXXXXX +0.04%
- X Month XXXXXX +0.22%
- X Months XXXXXX +1.50%
- X Year XXXXXX +2.40%

### CreatorRank: undefined [#](/creator/twitter::71542880/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::71542880/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::71542880/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXXX% [countries](/list/countries)  XXXX% [finance](/list/finance)  XXXX%

**Social topic influence**
[superior](/topic/superior) 2.38%, [acquisition](/topic/acquisition) 2.38%, [surge](/topic/surge) 2.38%, [$226m](/topic/$226m) 2.38%, [gilead sciences](/topic/gilead-sciences) 2.38%, [novartis](/topic/novartis) 2.38%, [$70b](/topic/$70b) XXXX%

**Top accounts mentioned or mentioned by**
[@novonordisk](/creator/undefined) [@sanofis](/creator/undefined) [@pharmaessentia](/creator/undefined) [@novonordisks](/creator/undefined) [@celltrioninc](/creator/undefined) [@gileadsciences](/creator/undefined) [@aspirepharmas](/creator/undefined) [@hikmapharma](/creator/undefined) [@akerotx](/creator/undefined) [@cencoraglobal](/creator/undefined) [@natcopharmaltd](/creator/undefined) [@regeneron](/creator/undefined) [@arcusbio](/creator/undefined) [@kyowakirinus](/creator/undefined) [@pfizer](/creator/undefined) [@astellasus](/creator/undefined) [@omeroscorp](/creator/undefined) [@mercks](/creator/undefined) [@novartis](/creator/undefined) [@merck](/creator/undefined)

**Top assets mentioned**
[Gilead Sciences, Inc. (GILD)](/topic/gilead-sciences) [Novartis AG (NVS)](/topic/novartis)
### Top Social Posts [#](/creator/twitter::71542880/posts)
---
Top posts by engagements in the last XX hours

"Grifols Biotest to launch Yimmugo in USA"  
[X Link](https://x.com/ThePharmaLetter/status/1976666619180122204) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-10T15:10Z 25.3K followers, XXX engagements


"@sanofi's high-dose influenza vaccine demonstrates superior protection"  
[X Link](https://x.com/ThePharmaLetter/status/1980542022646686064) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-21T07:49Z 25.3K followers, XX engagements


"Acquisition strengthens @AspirePharmas strategic portfolio"  
[X Link](https://x.com/ThePharmaLetter/status/1981063150892909036) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-22T18:20Z 25.3K followers, XXX engagements


"Ipsen lifts guidance as rare disease sales surge in third quarter"  
[X Link](https://x.com/ThePharmaLetter/status/1981063919805551066) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-22T18:23Z 25.3K followers, XXX engagements


"Ipsen to acquire French biotech ImCheck"  
[X Link](https://x.com/ThePharmaLetter/status/1981064355367309504) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-22T18:25Z 25.3K followers, XXX engagements


"Bristol Myers to launch Cobenfy in UK at a list price equal to the USA"  
[X Link](https://x.com/ThePharmaLetter/status/1970854508998824421) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-09-24T14:15Z 25.3K followers, XXX engagements


"@Celltrioninc presents positive RWE on switching from IV to SC infliximab"  
[X Link](https://x.com/ThePharmaLetter/status/1975581046767759483) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-07T15:16Z 25.3K followers, XX engagements


"@novonordisk axes cell therapy research in sweeping overhaul"  
[X Link](https://x.com/ThePharmaLetter/status/1978018364774547604) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-14T08:41Z 25.3K followers, XX engagements


"India's @NATCOPharmaLtd takes $226m strategic stake in Adcock Ingram"  
[X Link](https://x.com/ThePharmaLetter/status/1978019449765527659) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-14T08:46Z 25.3K followers, XXX engagements


"@Regeneron plans FDA filing based on latest DB-OTO data"  
[X Link](https://x.com/ThePharmaLetter/status/1978019625435631889) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-14T08:46Z 25.3K followers, XX engagements


"@AstellasUS' zolbetuximab misses Phase II goal"  
[X Link](https://x.com/ThePharmaLetter/status/1978780568155234502) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-16T11:10Z 25.3K followers, XX engagements


"@OmerosCorp rockets on news of deal with @novonordisk"  
[X Link](https://x.com/ThePharmaLetter/status/1978780782081519832) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-16T11:11Z 25.3K followers, XX engagements


"@GileadSciences highlights HIV pipeline at European AIDS Conference"  
[X Link](https://x.com/ThePharmaLetter/status/1978781627397419414) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-16T11:14Z 25.3K followers, XX engagements


"ESMO 2025: PSMAddition data show @Novartis Pluvicto delays prostate cancer progression"  
[X Link](https://x.com/ThePharmaLetter/status/1980302261025927676) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-20T15:57Z 25.3K followers, XXX engagements


"@novonordisk's oral GLP-1 approved to cut MACE risk in type X diabetes patients"  
[X Link](https://x.com/ThePharmaLetter/status/1980307665709658460) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-20T16:18Z 25.3K followers, XX engagements


"FDA accepts @sanofi's Tzield for expedited review"  
[X Link](https://x.com/ThePharmaLetter/status/1980308285191499865) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-20T16:21Z 25.3K followers, XXX engagements


"Elevara Medicines closes $XX million Series A financing"  
[X Link](https://x.com/ThePharmaLetter/status/1981063721939325366) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-22T18:22Z 25.3K followers, XXX engagements


"@Merck commits over $70B to US R&D center"  
[X Link](https://x.com/ThePharmaLetter/status/1981064149842219230) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-22T18:24Z 25.3K followers, XX engagements


"@sanofi's efdoralprin alfa meets Phase II endpoints"  
[X Link](https://x.com/ThePharmaLetter/status/1981064261439836277) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-22T18:25Z 25.3K followers, XX engagements


"Breakthrough designation for @Genmabs Rina-S in USA"  
[X Link](https://x.com/ThePharmaLetter/status/1960974454424519164) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-08-28T07:55Z 25.3K followers, XXX engagements


"Change goes on at @novonordisk with new board to be elected"  
[X Link](https://x.com/ThePharmaLetter/status/1981064695218934056) [@ThePharmaLetter](/creator/x/ThePharmaLetter) 2025-10-22T18:26Z 25.3K followers, XXX engagements